ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0022

Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients

Erika Hubbard1, Prathyusha Bachali2, Kathryn Kingsmore Allison1, Amrie Grammer1 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, Gene Expression, genomics, immunology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0013–0039.5) Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We previously developed a novel machine learning (ML) pipeline leveraging analysis of gene expression data to identify subsets of SLE patients with common molecular patterns of disease, endotypes[1]. These molecular subsets had significant differences in clinical characteristics, the frequency of subsequent flares, and clinical responsiveness to a lupus biologic, tabalumab. The current study makes use of the ML classifier to determine endotype membership in an independent validation cohort of SLE patients.

Methods: Gene expression by RNA-sequencing of whole blood and clinical metadata were collected from 91 SLE patients from two clinical trials (NCT03626311 and NCT03180021). Patients met ACR classification criteria of SLE and patients from one trial had renal biopsies at the time gene expression was measured. A random forest classifier trained on 2183 lupus patient gene expression profiles was used to predict endotype membership of the 91 patients. Lupus Cell and Immune Score (LuCIS), a continuous score measuring the extent of modular immunologic abnormalities determined by ridge-penalized logistic regression, was also calculated for each patient.

Results: The ML prediction of independent SLE patients into endotypes yielded eight subsets with molecular patterns mirroring those found previously in a development and testing cohort of 3166 patients (Figure 1). Endotypes were designated A-H, with A representing the group with the least number of transcriptional lupus-related aberrancies and H representing the group with the greatest immunologic perturbations. Groups H, A, C, and E were comprised of the greatest number of patients whereas B and G were small and underrepresented in this cohort. Endotype H contained the greatest number of patients with proliferative lupus nephritis (LN) whereas no patient with LN was found in subset A or B. Serum complement differed among the subsets, with the more immunologically active having lower levels. LuCIS values reflected the immunological activity of the subsets but did not correlate with SLEDAI, although they were moderately, inversely correlated with serum C3 and C4 levels (Figure 2). Eight patients had moderate/severe flares during the six months of the trials, of whom all had elevated LuCIS scores at baseline.

Conclusion: A novel endotyping pipeline based on transcriptional profiles and ML accurately identified patient endotypes in new datasets. Patients in the endotypes with the least immunologic activity did not have proliferative nephritis and also experienced no lupus flares during the subsequent six months. Endotyping SLE patients based on gene expression profiles can provide important prognostic information and provide novel molecular insights in support of personalized management.

1. Kim YH, Park MR, Kim SY, Kim MY, Kim KW, Sohn MH. Respiratory microbiome profiles are associated with distinct inflammatory phenotype and lung function in children with asthma. J Investig Allergol Clin Immunol. 2023 Jun 1:0. doi: 10.18176/jiaci.0918. Epub ahead of print. PMID: 37260034.

Supporting image 1

Figure 1. Identification of Endotypes Among 91 SLE Patients
Molecular subsets identified by a random forest algorithm using gene set variation analysis (GSVA) enrichment scores of 26 immune/inflammatory modules. Clinical metadata for each patient (x-axis) was annotated as shown. Heatmap constructed in R using the ComplexHeatmap package.

Supporting image 2

Figure 2. LuCIS Correlations with Clinical Data
Pearson correlations of LuCIS values with baseline clinical characteristics. Each data point is colored by endotype membership. Plots were constructed in R using the ggplot2 package.


Disclosures: E. Hubbard: None; P. Bachali: None; K. Kingsmore Allison: None; A. Grammer: None; P. Lipsky: None.

To cite this abstract in AMA style:

Hubbard E, Bachali P, Kingsmore Allison K, Grammer A, Lipsky P. Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/validation-of-a-transcriptomic-based-machine-learning-model-to-establish-the-endotype-of-sle-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-a-transcriptomic-based-machine-learning-model-to-establish-the-endotype-of-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology